by Travis Johnson, Stock Gumshoe | February 7, 2014 3:44 pm
This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.
Source URL: https://www.stockgumshoe.com/reviews/oxford-club/this-small-niche-player-has-a-first-mover-advantage-on-the-complete-cure-for-a-disease-thats-deadlier-than-cancer/
Copyright ©2024 Stock Gumshoe unless otherwise noted.
A large insurer Y is selling below book. I’ve never held it … Morningstar has been a fan over the years when it is cheap. Anybody ever look at this one?
I watched sdrl bounce off 35.20 three times and bought at 35.50. Bought at 35.50.
If they don’t cut the div. I think the stock will break 40 this year. If they don’t collect
the div for a couple years
Travis, thanks for your analysis of aortic stenosis cure, a question you answered even before I asked. I appreciated the run down on St. Jude and Medtronic. Was GMRCs run up totally a result of KOs new interests? There was a huge volume spike the day before the news came out.
Travis I really wish I had found Gumshoe far earlier , I have already learned so much from you as to investing after spending$$$$$$$ on overhype newsletters that were no real help. For right now I have stopped bio-tech investing; perhaps prior invest too much biased by emotion/personal reasons. If you not careful I think maybe Karma take over bio-tech end OTOH might be good for both. Unknown/unseen cannot be quantified. Please continue good you do.